Introduction: COPD is a leading cause of death worldwide; however, prevalence estimates have varied considerably in previous studies. This study aimed to determine the prevalence and severity of COPD in Copenhagen using data from the 4th examination of The Copenhagen City Heart Study, to investigate the relationship between tobacco consumption and COPD, and to characterize the subjects with COPD with regard to BMI, dyspnoea, treatment with respiratory medication and co-morbidities. Methods: 6236 people participated. All non-asthmatic participants aged 35 years or older with adequate lung function data were included for the final prevalence analyses (n Z 5,299). COPD staging was done according to the GOLD criteria. Results: The overall prevalence of COPD was 17.4%. The prevalence increased with age and was higher among males. 6.2% had mild COPD, 9.2% had moderate COPD, and 2.0% had severe or very severe COPD. Tobacco consumption was closely linked to both prevalence and disease severity. Subjects with COPD had lower mean Body Mass Index (BMI) and more frequently a BMI < 21 kg/m 2 . Dyspnoea was correlated to lung function but a substantial number of participants with severe COPD experienced no dyspnoea. Only a minority of subjects with COPD received pulmonary medication. COPD was associated with cardiovascular disease and cancer. Conclusion: The prevalence of COPD in Denmark is among the highest in the world. It is closely correlated to smoking and age. It is accompanied by substantial co-morbidity and it is grossly under treated. 
Introduction
COPD is characterized by chronic inflammation of the airways gradually leading to airflow limitation. Smoking is by far the leading cause of COPD in Western countries and recent findings suggest that at least 40% of all smokers will develop any COPD and 25% clinically significant COPD. 1 In the early stages of the disease symptoms are widely neglected often delaying diagnosis until the disease has progressed to an advanced stage.
Every year COPD is responsible for millions of deaths worldwide and is the cause of morbidity to an even greater extent. Smoking prevalence is slowly declining in the Western world but continues to rise elsewhere and it is estimated that the global impact of COPD will increase further in the years to come. 2e4 Estimates of prevalence from industrialized countries range widely reflecting both true differences as well as differences in the definition of COPD and the diagnostic tools used in the surveys. Most studies find a prevalence of 10e15% in the population above 35e40 years of age. 5e16 The Copenhagen City Heart Study is one of the largest and longest running cohort studies focusing on pulmonary aspects. In this paper we used the latest data to give an updated estimate of prevalence of COPD in Copenhagen along with a determination of disease severity. To facilitate comparison with other studies the prevalence and severity of COPD were stated in various age groups and the participants were characterized by smoking history. In addition, we wanted to describe the participants in terms of Body Mass Index (BMI), co-morbidities, dyspnoea and treatment with respiratory medications as these variables have been shown to be of prognostic importance. 17 
Methods
All subjects included in this study participated in the Copenhagen City Heart Study, a prospective epidemiologic study initiated in 1976e1978. A sample of 19,698 subjects aged 20 years or older was selected at random, after age stratification in 5-year age groups, from residents of Copenhagen. 14,223 subjects participated in the initial survey at Copenhagen University Hospital. They were all reinvited to participate in later surveys along with additional subjects in the youngest age group. A total of 6237 attended the fourth survey (response rate 50%). The participants filled out a self-administered questionnaire, which was checked together with an investigator to ensure that the responses were accurate.
At this survey, forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC) were measured with a dry wedge spirometer (Vitalograph, Maidenhead, UK), calibrated daily with a 1 L syringe. At each examination three sets of values were obtained and as a criterion for correct performance of procedure at least two measurements differing by less than 5% had to be produced. Only pre-bronchodilator measurements were available. The results from asymptomatic neversmokers were used to calculate prediction values (FEV 1 %pred) for FEV 1 in the study sample. The prediction equations were:
Men: FEV 1 (ml) Z À3763e35.2 * age (years) þ 52.9 * height (cm).
Women: FEV 1 (ml) Z À1431e28.5 * age (years) þ 34.5 * height (cm).
The FEV 1 values obtained from these equations were concordant with reference values for normal subjects published by The Danish Lung Association. 18 The spirometric cut off values used in the GOLD classification was applied for classifying disease severity: Subjects with normal spirometry were labelled as "no COPD" regardless of lung symptoms.
Subjects 35 years of age or older with adequate lung function data were included for analysis. Subjects younger than 35 years of age were excluded because prevalence of COPD was thought to be negligible and uncertain. All subjects who gave an affirmative answer to the question "do you have asthma?" were considered asthmatics in accordance to conventions from previous epidemiological studies. 19 Because many of those reporting to have asthma by definition fulfilled the criteria of COPD the prevalence analyses were conducted both with and without these subjects. In all other calculations the asthmatics were excluded.
Smoking status was obtained from the questionnaire and subjects were classified as smokers, ex-smokers or neversmokers. Number of pack-years was calculated for exsmokers and smokers (1 pack-year Z 20 cigarettes per day for one year).
At the physical examination weight and height were recorded for every participant and BMI was calculated. In each GOLD group mean BMI was calculated as well as the percentage with BMI<21 kg/m 2 . Co-morbidity was established from the questionnaire in which the participants were asked about manifestations of ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, if they had diabetes, or if they had or had ever had cancer. A previous history including myocardial infarction, coronary artery by-pass grafting, percutaneous coronary intervention or chest pain on exertion was taken as indicators of ischaemic heart disease. Stroke or a history within 10 years of paralysis, difficulty controlling movement of a limb or the face, blindness in one or both eyes or disturbances of speech were taken as indicators of cerebrovascular disease. Pain in one or both legs after a period of walking, which could be relieved by stopping was considered indicative of peripheral arterial disease.
Dyspnoea was ascertained from the questionnaire. Subjects were asked if they got breathless while walking fast or up hill, while walking with individuals of their own age at normal pace, if they occasionally had to stop to catch their breath while walking at their own speed, if they got breathless while dressing or if they were breathless at rest. Severity of dyspnoea was graded accordingly from 0 to 5 where 0 was no dyspnoea and 5 was dyspnoea at rest. Subjects answering affirmatively to the question "do you occasionally have to stop while walking at your own speed" was categorized as grade 3 which was considered to be equivalent to a MRC (Medical Research Council) dyspnoea score of 3. 20 In the questionnaire the participants were asked if they used medication for asthma or bronchitis on a daily or near daily basis, but the type and dose were not reported.
The study protocol was approved by the local ethics committee and informed consent was obtained from all participants.
Statistics
The prevalence of COPD in various age groups is shown with exact 95% confidence intervals computed from the F distribution (based on the binomial cumulative distribution function). The prevalence of COPD in various age groups according to severity is also shown with approximate 95% confidence intervals using Goodman's simultaneous method for multinomial proportions. 21 The distribution of BMI was approximately normal both in the total study population and within the GOLD groups. For each GOLD group mean BMI is shown with approximate 95% confidence intervals derived from the mean value þ/À 1.96 SE. Student's t-test was used when comparing the mean BMI in the two genders. The distribution of age and FEV 1 %pred was also approximately normal and the Student's t-test was used correspondingly. The distribution of pack-years was reversely j-shaped and the ManneWhitney test was used when comparing median pack-years between the genders. In all other instances data was qualitative and the Chi-square test was used to calculate p-values testing for equality between genders and between subjects with and without COPD. SPSS 12.0 was used for all calculations. 22 
Results
The study sample consisted of 5299 subjects, 3014 women and 2285 men, of whom 368 reported to have asthma. The mean age in the total study population was 62.6 years; women on average being two years older than men (63.5 years vs. 61.4 years, p < 0.001).
The prevalence of COPD in various age groups is shown in Table 1 . Excluding asthmatics, the overall prevalence of COPD was 17.4% in the study sample; increasing gradually with age from 7.1% in the youngest age group to 26.9% among subjects 80 years or older. COPD was more prevalent in men than in women (19.4% vs. 15.8%, p < 0.001), particularly among the elderly. When asthmatics were included in the analyses the overall prevalence of COPD rose approximately 2% with no difference between the genders.
In Table 2 the prevalence is shown according to severity of COPD using GOLD criteria. GOLD stages 3 and 4 are combined due to low numbers; 6.2% had mild COPD (GOLD 1), 9.2% had moderate COPD (GOLD 2) and 2.0% had severe or very severe COPD (GOLD 3 þ 4). COPD was more prevalent among men in all age groups and for all degrees of severity except from moderate COPD among those between 65 and 79 years of age where the prevalence was equal among the genders. Table 3 shows prevalence and severity of COPD in correlation to cumulated tobacco consumption. The prevalence of COPD increased from 7.9% among never-smokers to 31.2% among individuals with a tobacco consumption of 30 pack-years or more. The severity of COPD followed the exact same pattern rising gradually with increasing tobacco consumption. The median cumulated tobacco consumption was higher in men (27 pack-years vs. 18 pack-years, p < 0.001) but the correlation between smoking and COPD was identical in the two genders. 51.1% of the subjects with COPD still smoked with little difference between the GOLD stages. At all stages of COPD, there were more male than female smokers (55.3% vs. 47.7%, p < 0.005).
Mean BMI was slightly lower among subjects with COPD compared to subjects without COPD (25.0 kg/m 2 vs. 26.3 kg/m 2 , p < 0.001). After adjustment for age, gender, pack-years and current smoking status the difference between the two groups became bigger. Subjects with COPD had a BMI of 1.9 kg/m 2 (95% confidence interval 1.3e2.5 kg/m 2 ) less than subjects without COPD. Women had a mean BMI of 1.3 kg/m 2 (0.5e2.1 kg/m 2 ) less than men. As shown in Table 4 , there was only a small and statistically non-significant difference in mean BMI between the GOLD groups. Adjustment for age, gender, pack-years and smoking status did not alter this. The fraction with a BMI of less than 21 kg/m 2 was higher among subjects with COPD compared to subjects without COPD (12.6% vs. 8.1%, p < 0.001), particularly driven by subjects with severe disease. The fraction with BMI of less than 21 kg/m 2 was higher among women at all stages of COPD (12.4% vs. 4.2%, p < 0.001) and among smokers (11.6% vs. 7.5% p < 0.001). The prevalence of COPD among obese individuals with BMI of 30 kg/m 2 or more was lower than among the rest of the population (11.2% vs. 18.6%, p < 0.005) due to a lower occurrence of mild and moderate disease. In contrast mean FEV 1 %pred was slightly lower among the obese compared to the rest of the population (89.8% vs. 92.6%, p < 0.001). The obese were a little older (64.9 years vs. 62.3 years, p < 0.001) whereas the sex distribution was the same.
As shown in Table 4 , dyspnoea increased with increasing severity of COPD. Subjects with severe or very severe COPD were on average moderately dyspnoeic corresponding to a dyspnoea score of 2 whereas subjects with moderate COPD on average had mild dyspnoea and a dyspnoea score of 1. There was no difference in dyspnoea score among subjects with no COPD and subjects with mild COPD. Dyspnoea corresponding to a score of 3 or more became increasingly frequent with increasing GOLD stage. Women with COPD on average had slightly higher dyspnoea scores than men and more often had dyspnoea scores of 3 or more (18.9% vs. 14.4%, p Z 0.05).
Only 8.3% of subjects with COPD received some kind of respiratory medication. As shown in Table 4 the treatment prevalence increased step-wise with severity of COPD. Among the subgroup with a dyspnoea score of 3 or more the treatment prevalence was 19.3%. Among subjects without asthma or COPD 1.8% were treated with respiratory medications. At all stages of COPD women were treated more often than men (11.1% vs. 5.6%, p < 0.005).
As shown in Table 5 , the prevalence of arteriosclerotic disease (either manifest or symptoms indicating arteriosclerosis) was higher among subjects with COPD compared to the rest of the population (ischaemic heart disease 13.3% vs. 9.5%, p < 0.001, cerebrovascular disease 23.0% vs. 17.8%, p < 0.001, and peripheral arterial disease 22.9% vs. 16.0%, p < 0.001) and tended to increase with severity of COPD. There was a general male predominance among subjects with ischaemic heart disease and apoplexia. There was a stepwise increase in the prevalence of present or former malignancies with increasing GOLD stage, women being Values are shown for each gender separately and combined. Prevalence of COPD is shown in percentage, in different age groups, with exact 95% confidential intervals in brackets, with and without asthmatics. In parenthesis the absolute number of subjects with COPD is shown in relation to the total number of subjects within the age group. Values are shown for each gender separately and combined. Prevalence of COPD is shown as percentage in different age groups with approximate 95% confidence intervals in brackets, according to severity of disease, using the GOLD classification. In parenthesis the number of subjects with COPD is shown in relation to the total number of subjects within the age group.
affected substantially more than men (12.8% vs. 6.4%, p < 0.001). Diabetes was equally prevalent among individuals with and without COPD (5.4% vs. 5.0%, p > 0.25) with male predominance. Subjects with COPD were significantly older and the average age increased gradually with severity of COPD, from 61.4 years among subjects without COPD to 70.8 years among those in GOLD group 3 þ 4. As expected, the prevalence of co-morbidity rose stepwise with age. It was consistently a little higher, regardless of age, in the subgroup with COPD, rising from 23.2% among subjects aged 35e49 years to 63.9% among subjects older than 80 years. Among subjects without COPD it rose from 19.4% to 62.2%.
Discussion
We found an overall prevalence of COPD of 17.4% among individuals 35 years of age or older participating in the 4th exam of the Copenhagen City Heart Study. This is higher than previously reported in this population. 23 The COPD prevalence follows the smoking prevalence but with a considerable delay in time as it takes a prolonged period of smoking to develop the disease. The smoking prevalence in Denmark reached a peak around 1970 after which it has declined slowly. However, it is primarily the light smokers who have given up smoking and the total tobacco consumption has declined at a much slower rate. 24 Also, the life expectancy has gradually increased and the proportion of elderly people has become larger. As the COPD prevalence is markedly higher in the elderly population the total prevalence would tend to increase. A combination of these factors could explain why the COPD prevalence has increased, while at the same time the smoking prevalence has decreased.
Estimates of COPD prevalence from studies in other developed countries have ranged from 5 to 19% with the majority being in the vicinity of 10%.
5e16 Differences in demographics, diagnostic tools, smoking patterns etc. are the most likely explanation to the variance. The overall prevalence in our study is among the highest reported so far mainly due to the large fraction of women with COPD. The prevalence among Danish women is lower than among the men but extraordinarily high in an international context. 6, 7, 9, 10, 14 It reflects the sad fact that Danish women were among the first to take up smoking and for many years had the highest consumption in the world. 24 The tobacco consumption among Danish men does not differ from the consumption in most European countries. 24 Recent results from an epidemiological trial in a rural part of Denmark, where the tobacco consumption is smaller and the socioeconomic conditions are better than in Copenhagen, have reported slightly lower prevalence rates, but a similar sex distribution. 25 In accordance with previous studies we found that both prevalence and severity of COPD was closely linked to the cumulated tobacco consumption. The finding that approximately 50% of subjects with COPD still smoked was not surprising but it highlights the need for a continuous effort against smoking. It is noteworthy, though, that 13.8% of the subjects with COPD had never smoked which corresponds to a prevalence of COPD of 7.9% among never-smokers. Most of these individuals were old and had mild to moderate disease. Thus, COPD is primarily, but not exclusively, associated with smoking. Not surprisingly, the prevalence and the severity of COPD increased with age due to a combination of larger tobacco consumption and the cumulated physiological decline over time.
Our study is impeded by several methodological limitations and the prevalence in the study sample may not accurately reflect the "true" prevalence in the entire population. International guidelines recommend postbronchodilator spirometry and reversibility testing before a diagnosis is made and staging is carried out. In our study the reversibility test was left out and some of the subjects labelled with COPD may have had undisclosed asthma. A small physiological improvement in the dynamic lung volumes is often observed following bronchodilation and some of the individuals with mild COPD may have had normal lung function if they had been bronchodilated before testing. 26 Also, there is a physiological decline with increasing age in the FEV 1 /FVC ratio. Using a fixed ratio of 0.7 results in a higher prevalence among the elderly including some with no symptoms and no tobacco exposure. According to the GOLD definition these subjects have COPD but whether it is a "genuine" disorder or merely an insignificant age related phenomenon is continously debated. In this sense our estimate of mild to moderate COPD may be too high. However, other factors may have lead to underestimation of the prevalence. The response rate at the fourth survey was only 50% and our results may suffer from non-response bias. The extent and importance of the bias is difficult to determine as the local ethics comittee has not allowed investigation of non-responders. A previous study of non-responders in The Copenhagen City Heart Study reported that non-responders on average were less healthy than the responders 27 whereas recent studies of nonresponse bias in danish and swedish surveys suggest that bias is relatively small and of less importance.
28e30 Probably, the most severely affected and dyspnoeic COPD patients did not show up for examination as it requires some physical effort.
Within recent years it has been acknowledged that COPD is not restricted to the lungs but is accompanied by systemic manifestations with elevated inflammatory markers, weight loss and muscle wasting. 31, 32 BMI is an important prognostic factor and is included in the BODEindex. 17 Thus, our finding that mean BMI was reduced in subjects with COPD was expected. We also expected to find an inverse correlation between severity of disease and BMI. Instead we found that BMI tended to rise with increasing GOLD stage. Nevertheless, the fraction with BMI of less than 21 was higher among subjects with severe COPD. Thus, the BMI values among subjects with severe disease were more extreme and the subjects were more likely to be either underweight or obese. The physical inactivity accompanying dyspnoea could explain the tendency towards obesity and measures of fat free mass may more accurately have reflected the systemic manifestations and given a more uniform result. Alternatively, it may only be a subset of subjects with severe disease who have systemic manifestations. Previously, the association between BMI and COPD has primarily been investigated in severely affected patients committed frequently to the hospital. In our cohort most subjects had mild to moderate COPD whereas only a minor part had severe disease. The systemic effects are likely to be of less importance at the early stages of COPD but become more pronounced with disease progression. The lower prevalence of COPD among obese individuals may not be real since obesity is a known cause of lung restriction, resulting in higher FEV 1 /FVC ratios. This is supported by the slightly lower FEV 1 %pred among the obese and undoubtedly some had reduced lung function of mixed type with both airway restriction and obstruction. As well as BMI, dyspnoea is a prognostic factor in COPD. 33 In addition, dyspnoea is of importance when evaluating patients for pulmonary rehabilitation. As expected we found that dyspnoea became more frequent and worse with increasing GOLD stage. However, it is noteworthy that a large fraction of the individuals with COPD reported no or only very little dyspnoea even at advanced stages of disease. It highlights the importance of performing spirometry in the population at risk. From our data it is possible to estimate the need for pulmonary rehabilitation in the general population. Subjects with disease in GOLD stage 2e4 with dyspnoea corresponding to a score of 3 or more would be potential candidates. Of the subjects with COPD 14% fulfill these criteria which vastly exceeds the current capacity in Copenhagen e and probably elsewhere. Only a minority of the subjects with COPD received regular pharmacological treatment. Even among subjects with severe dyspnoea and advanced disease the numbers treated with respiratory medications were very low. Optimal pharmacological treatment has well documented effects on both the course of disease and on symptoms 34e36 and a strengthened and continuous educational effort primarily targeted at the general practitioners is called for to improve this situation.
Symptoms indicative of arteriosclerosis were present in a large fraction of the study population. As the symptoms are not specific to arteriosclerotic disease the true prevalence is likely to be somewhat lower. As previously demonstrated we found that subjects with COPD were older and more burdened with cardiovascular disease and cancer than the rest of the population. 37, 38 As smoking predisposes to atherosclerosis and many types of cancer, this is not surprising. The high frequency of curable breast cancer and gynaecological cancers probably explain at least some of the difference in cancer prevalence between the genders.
In conclusion, our study is among the largest studies in the world on COPD prevalence. Subjects with COPD were thoroughly characterized with regard to age, severity of disease and smoking status, which allows comparisons with other studies. Further, as one of the first studies our subjects with COPD are described by variables of prognostic importance i.e, BMI, dyspnoea, co-morbidity and medication with pulmonary medicine. Our study confirms that COPD is a widespread and very common disease e perhaps more so than what has previously been believed. It is closely correlated to smoking and prevalence of COPD and disease severity rise with increasing age. COPD is accompanied by an increased occurrence of cardiovascular disease and cancer and the patients are grossly under treated. Even with continued decreasing tobacco consumption COPD will remain a major health problem for many years to come.
